TB-500 Satisfaction Trends Over Time: What Real Users Report
HealthRX.com
No measured satisfaction trend exists for TB-500
See the public record for TB-500
At a glance
- Compound / Synthetic 7-amino-acid fragment (residues 17 to 23) of thymosin beta-4 [1]
- Closest human report / 75% of the 4 knee-pain patients given BPC-157 plus thymosin beta-4 reported significant improvement; the thymosin beta-4 form was not specified [2]
- FDA adverse-event reports naming TB-500 / None through March 26, 2025 [1]
- FDA compounding lists / On none of the three pharmacy-list categories or the outsourcing-facility list [3][4][5]
- Sports status / Prohibited at all times, WADA S2.3 [6]
Is there any measured satisfaction trend?
A trend needs the same measure taken more than once in a defined group. We found no such repeated measurement for TB-500. What has changed recently is the regulatory record, not the clinical one [1][7][8].
What human reports exist
The closest thing to a user report in the published record is a 2021 retrospective chart review by Lee and Padgett at one Florida clinic. Of 16 patients reached by phone after intra-articular peptide injections, 12 received BPC-157 alone and 4 received BPC-157 plus thymosin beta-4; 75% of the 4 reported significant improvement, against 11 of 12 on BPC-157 alone. There was no control group, no validated tool, and patients were recalling their results. It was not a TB-500 satisfaction study, and the form of thymosin beta-4 used was not specified [2].
FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment attached; FDA found no published case reports [1]. Its BPC-157 review describes a 40-year-old woman who injected a research-purpose BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she retried it. Because the product held two peptides, FDA said it cannot tell whether either one caused it [9].
Trials of full-length thymosin beta-4, a different molecule, do not fill the gap. A phase 1 study enrolled 54 healthy volunteers in single-dose cohorts receiving intravenous recombinant human thymosin beta-4 or placebo at 0.05 to 25 microgram/kg; adverse events were mild to moderate, with no serious ones [10].
What people on Reddit report
Two accounts from one early-use thread on a blended peptide product, covering side effects and how the product was sourced and dosed.
Sleep is sabotaged. Especially REM. Averaging 10-15 points lower on my sleep score consistently due to restlessness and poor REM.Read the source discussion
5 on 2 off was recommended by the clinic I get it at. Just going with their recommendation. The bottle says TB-500.Read the source discussion
Questions worth asking
Why online reports cannot be read as a trend
FDA found several salts and derivatives, including different active moieties, sold under the TB-500 name, and found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1]. The material is sold as research-use injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]. Online posts about products sold under that name may not describe the same substance.
What the regulatory record shows
- TB-500 is not FDA-approved, and it appears in none of the three categories on FDA's state-licensed pharmacy list or on its outsourcing-facility list [1][3][4][5].
- FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the bulks list, citing no human data, poor characterization and immunogenicity risk [1]. The Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026; advisory committee recommendations are non-binding [7].
- An HHS draft policy filed October 28, 2026 says HHS does not intend enforcement action against certain licensed pharmacies and physicians compounding TB-500 acetate for injection if conditions are met. It establishes no rights and is not an approval [8][11].
- WADA names thymosin-beta4 and its derivatives, including TB-500, in S2.3: prohibited at all times, in and out of competition [6][12].
- FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities; it found no nonclinical toxicity studies and no human pharmacokinetic data by any route [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Do Reddit posts and review-site ratings count as evidence?
Is TB-500 approved or compoundable?
What side effects are documented?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long should I be on TB-500?
No duration guidance is given. No repeated satisfaction measurements over time exist for TB-500, and there is no human data on TB-500 itself, so how long use affects results is not established. The only human report is a 2021 chart review of 16 patients, with no control group and no validated tool.
Is TB500 better than BPC-157?
No comparison of TB-500 with BPC-157 for effectiveness exists. The closest human data involve BPC-157: in a 2021 retrospective review, 11 of 12 patients on BPC-157 alone reported significant improvement. That review had no control group and was not a TB-500 satisfaction study.
Is TB-500 worth it for daily maintenance?
Not established. There is no human data on TB-500 itself, no human pharmacokinetic data by any route, and no measured satisfaction trend over time. TB-500 is not FDA-approved, and FDA's stated concern for injectable TB-500 is immunogenicity.
References
Show all 13 referencesHide references
- U.S. Food and Drug Administration.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding. Bulk Drug Substances Used in Compounding | FDA
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Official web page.
- World Anti-Doping Agency.
- Reddit participants. Entering into week 3 of TB-500/BPC-157 (r/bpc_157). Accessed 2026-11-11.